Your browser is no longer supported. Please, upgrade your browser.
Lyra Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.54 Insider Own1.40% Shs Outstand12.93M Perf Week-8.45%
Market Cap181.40M Forward P/E- EPS next Y-1.86 Insider Trans0.56% Shs Float9.52M Perf Month25.78%
Income-19.30M PEG- EPS next Q-0.56 Inst Own83.50% Short Float1.48% Perf Quarter7.73%
Sales- P/S- EPS this Y-170.50% Inst Trans10.50% Short Ratio0.73 Perf Half Y8.33%
Book/sh6.26 P/B2.18 EPS next Y7.50% ROA- Target Price- Perf Year-
Cash/sh6.14 P/C2.22 EPS next 5Y-4.80% ROE- 52W Range8.76 - 22.00 Perf YTD19.82%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.91% Beta-
Dividend %- Quick Ratio17.70 Sales past 5Y- Gross Margin- 52W Low55.93% ATR1.01
Employees38 Current Ratio17.70 Sales Q/Q- Oper. Margin- RSI (14)52.38 Volatility8.32% 7.07%
OptionableNo Debt/Eq0.00 EPS Q/Q-43.20% Profit Margin- Rel Volume0.56 Prev Close14.03
ShortableYes LT Debt/Eq0.00 EarningsMar 09 AMC Payout- Avg Volume191.76K Price13.66
Recom1.00 SMA201.53% SMA5013.60% SMA20011.26% Volume107,316 Change-2.64%
May-26-20Initiated William Blair Outperform
May-26-20Initiated Jefferies Buy $24
May-26-20Initiated BTIG Research Buy $28
May-26-20Initiated BofA/Merrill Buy $21
Mar-04-21 11:43AM  
Mar-02-21 04:05PM  
Mar-01-21 08:43AM  
Feb-17-21 08:00AM  
Feb-10-21 05:05PM  
Feb-01-21 05:06PM  
Jan-22-21 08:00AM  
Jan-15-21 12:11PM  
Jan-13-21 06:52PM  
Dec-07-20 08:00AM  
Dec-02-20 11:27PM  
Nov-12-20 04:05PM  
Nov-10-20 04:05PM  
Nov-02-20 11:34AM  
Oct-28-20 04:05PM  
Sep-10-20 06:00PM  
Sep-03-20 04:05PM  
Aug-05-20 04:05PM  
Aug-04-20 04:05PM  
Aug-03-20 02:40PM  
Jul-30-20 04:05PM  
Jul-24-20 08:30AM  
Jul-07-20 08:30AM  
Jun-25-20 08:00AM  
Jun-05-20 07:25PM  
May-28-20 04:05PM  
May-08-20 08:00PM  
May-05-20 09:31AM  
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
snyderman nancy lynn MDDirectorDec 16Buy9.721,0259,9631,025Dec 17 04:05 PM